

For Immediate Release

January 31, 2011



John H. Friedman of Easton Capital Investment Group Joins Sequella Board of Directors

Rockville, MD -- Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of infectious diseases, announced today that John Friedman has joined its Board as an Independent Director. Mr. Friedman brings more than 30 years of venture investment experience to the Sequella Board. He is the Founding and Managing Partner of Easton Capital Investment Group. Prior to founding Easton Capital, he was a founder and Managing General Partner of Security Pacific Capital Investors, a \$200-million private equity fund geared towards expansion financings and recapitalizations. Prior to joining Security Pacific, Mr. Friedman spent more than eight years at E.M. Warburg, Pincus & Co, where his last position was a Managing Director and Partner. Prior to Warburg Pincus, Mr. Friedman was an attorney with Sullivan and Cromwell.

Mr. Friedman holds a JD degree from Yale Law School and a BA degree, magna cum laude and Phi Beta Kappa, from Yale College. He currently serves on the Boards of Promedior, Experimed, Trellis Bioscience, Cardiovascular Systems, iTherX, and PlaySpan, portfolio companies at Easton Capital. He was co-chairman of the President's Council at the Cold Spring Harbor Laboratory and currently serves as a Trustee of The New Museum of Contemporary Art.

"We are delighted to welcome Mr. Friedman to our Board of Directors," said Dr. Carol A. Nancy, CEO of Sequella. "His long career in venture financing and building successful companies will be a great asset to Sequella as we reach our near-term value inflection points with our new antibiotic in Phase 2 clinical trials for TB and *Helicobacter pylori* infections. We look forward to working with John to build on these programs and continue our successes in identifying and developing novel drugs to treat unmet medical needs in infectious diseases."

Mr. Friedman stated, "I am honored to join a company led by such an eminent team. Dr Nancy is rightly recognized as one of the key opinion leaders in the entire world in TB research, and I am confident that Sequella will succeed in developing new treatment paradigms to solve some of the more vexatious unmet medical needs in infectious disease."

###

About Sequella, Inc.

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases. The company leverages its global influence, R&D platforms, and disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity. For more information, please visit www.sequella.com.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

MEDIA CONTACT: Alan Klein, Executive Vice President, Corporate Development, Sequella, Inc., 301-762-7776 or alanklein@sequella.com